A Review of Vancomycin Population Pharmacokinetic Studies in Adult Critically Ill Patient
Year: 2012
Type: conference-paper
Abstract: Background E fficacy of vancomycin, the most recommended anti!M RSA antibiotics, was best represented with A U C 24 /M I C >400 which was greatly determined by phar macokinetic (P K ) and pharmacodynamics parameters.G iving a standard dose of vancomycin to any populations with deviated phar macokinetic parameters, as found in the critically ill population, will impact on the achievement of A U C 24 and M I C coverage.O bjective T his review was conducted to investigate the profile of critically ill adult P K parameters and examine the effects of the different P K parameters to the achievement of A U C 24 and maximum M I C coverage.M ethod L iterature search was conducted using Pub M ed and T rip Database from the database inception to July 2012.Published articles which present the critically ill population P K equation model will be included in the review.Reference case analysis will be used to calculate the P K parameters, A U C 24 , and maximum M I C coverage.Result T here were 5 critically ill adult population P K studies met the inclusion criteria.E ach study shows specific P K equation model for V d and C L .O nly 4 studies were included in the reference case analysis.Result from reference case analysis for the V d and C L were: 69L , 58.8L , 104.04L, 49.2L ; and 4.29L/h, 5.12L/h, 3.586L/h, 3.19L/h, consecutively.T he A U C 24 (in mg.hr.L -1 ) and maximum M I C of M RSA strain (in mg/L) that still could be covered by giving standard dose of vancomycin were: 466.2, 390.63, 557.72, 626.96; and 1.16, 0.98, 1.39, 1.56.While, the V d, C L , A U C 24 , and maximum M I C of M RSA resulted from general population equation model calculation were 37.2L , 2.6L/h, 769.23mg.hr.L -1 , and 1.92mg/L .Conclusion G iving standard dose of vancomycin to the critically ill population yielded a lower achievement of total A U C 24 leading to lower M I C of M RSA strain that still could be covered.C lose monitoring and dose adjustment, if needed, should be given to ensure the achievement of desired target treatment.
Authors: Eko Setiawan, Preecha Montakantikul
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2621105126
